This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!
Content:
- What are options after steroids?
- ... Show More
Oct 14
Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease
This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of a ... Show More
26m 23s
Oct 7
Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging
This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocar ... Show More
28m 52s
Sep 23
Episode 165: CLL Updates Series, Pt. 2 – Relapsed/Refractory in 2026
This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhi ... Show More
22m 22s
Aug 2025
S2 Episode 1: Managing Side Effects and Maximizing Quality of Life in Multiple Myeloma Patients
Joseph Mikhael, MD, and Surbhi Sidana, MD, discuss the importance of balancing treatment intervals, managing side effects, and maximizing quality of life in multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.c ... Show More
23m 58s
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s